Navigation Links
Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
Date:8/8/2012

LONDON, Aug. 8, 2012 /PRNewswire/ -- Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company" or "Lightlake"), an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today compelling final data from a Phase II study of the Company's proprietary opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED). BED is a psychiatric condition that is manifested by recurrent episodes of eating unusually large amounts of food in a short period of time associated with a sense of lack of control over food intake.

BED is a major cause of obesity for those patients with addictive behavior towards food. It is the most chronic and common of all eating disorders with a significant cost to society, with 12 to 18 million people in the United States likely meeting the criteria for BED and a further 20 million people exhibiting bingeing behavior. It is significantly undertreated with no approved pharmacological therapies.

Patients receiving the naloxone nasal spray achieved the study's primary endpoint by exhibiting a statistically significant reduction in time spent per week binge eating compared to those patients who received a placebo nasal spray, reducing their bingeing by 125 minutes per week compared to 84 minutes per week for placebo-treated subjects (p=0.024).

The effect of the naloxone nasal spray was especially pronounced when comparing the baseline bingeing with the level of bingeing during the last week of treatment, with the patients receiving naloxone reducing their bingeing by 158 minutes per week compared to 101 minutes per week for placebo-treated subjects (p=0.018) during this period. Overall, 81% of patients completed the entire six-month study with no statistically significant difference in dropout rates between the placebo and the treatment groups and without any Serious Adverse Events (SAE) reported during the trial.
'/>"/>

SOURCE Lightlake Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019
2. Celltex Therapeutics Corporation Expands Laboratory Operations And Adds Depth To Its Management Team
3. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
4. Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 1
5. United Therapeutics Corporation Reports Second Quarter 2012 Financial Results
6. Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
7. United Therapeutics Corporation to Announce Second Quarter 2012 Financial Results Before Market Open on Thursday, July 26, 2012
8. Juventas Therapeutics Raises $22.2 Million Series B Financing
9. Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
10. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
11. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... IL (PRWEB) November 21, 2014 On ... competitors at the 2014 Emerging Medical Technologies Summit in ... Innovator Awards. Widely regarded among Silicon Valley investors ... medical device innovation, the win also positions Briteseed ... MedTech Innovator competition in 2015 and compete with other ...
(Date:11/22/2014)... November 21, 2014   ... Chief Commercial Officer zu KLOX    ... und Chief Financial Officer bestellt    ... Vermarktung seines jüngst zugelassenen Behandlungssystems zur Wundheilung zu beginnen ... das "Unternehmen") ist sehr erfreut, die folgenden personellen Veränderungen ...
(Date:11/21/2014)... Diego, CA (PRWEB) November 20, 2014 ... extended their Sartorius Entris Balance promotion . The ... customers seeking a durable, high accuracy, and easy-to-maintain balance ... made in Germany. It was designed to help customer’s ... affordable and a balance that is very durable. Sartorius ...
(Date:11/21/2014)... NY (PRWEB) November 20, 2014 The ... now available as an open access journal featuring the ... infrared fluorescent proteins to preserve photoresponsiveness in the retina ... Two-color fluorescent in situ hybridization using chromogenic substrates in ... for DNA, RNA, and protein electrophoresis , ...
Breaking Biology Technology:Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3
... Presented, CHARLES TOWN, W.Va., Nov. 23 ... a provider of treatment for,diabetic peripheral neuropathy ... concluded analysis of the recent volatility of ... Board of Directors., (Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO ...
... AMDL, Inc. (Amex: ADL,- News), headquartered ... and Jilin, China, through its wholly owned ... biopharma company that,engages in the development, manufacture ... The Company announced today that,the recent presentation ...
... University of Pittsburgh have created the best method so ... wide, a significant step in science,s increasing attempts to ... single molecule scale and provide smaller, faster, and more ... 26 in the Journal of the American Chemical Society ...
Cached Biology Technology:ReBuilder Medical Technologies, Inc.'s Recent Stock Price Volatility Explained 2AMDL Presentation of China Success Story from Rodman & Renshaw Annual Healthcare Conference Available at WallStreetReporter.com 2
(Date:11/18/2014)... 18, 2014   EyeLock Inc. , a ... MorphoTrust USA (Safran), a leading U.S. ... a strategic partnership to offer comprehensive biometric identity ... (MVA), airport screening and financial services markets. ... serves consumers through a nationwide network of 1,100 ...
(Date:11/7/2014)... professor, biomedical engineering, in the Grove School of ... have identified a molecule that could lead to ... forms of breast cancer. , Triple negative breast ... to aggressive proliferation and metastasis and a lack ... discovered the overexpression of intercellular adhesion molecule-1 (ICAM-1) ...
(Date:11/6/2014)... when that predator runs so fast that it essentially blinds ... the fastest creature on Earth. Some of these half-inch-long beetles ... miles per hour). The fastest human can do about five ... beetle, a person would have to hit 480 miles per ... peak speeds, everything becomes a blur. They can,t gather enough ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3The tiger beetle: Too fast to see 2
... Scientists will soon be exploring matter at temperatures and ... microseconds using powerful pulsed lasers. Matter in such states ... kilometres beneath the surface, and also in elusive "warm ... X-ray beamline ID24 at the European Synchrotron Radiation Facility ...
... , SAN FRANCISCO (Nov. 9, 2011; 12:50 p.m.) ... an investigational intravenous antiplatelet, showed patients can be "bridged" ... oral antiplatelet drugs until they undergo cardiac surgery. ... inhibition known to be associated with a low risk ...
... use of genetic analysis to help save a boy imperiled ... change in two localities, and on the secret lives of ... AAAS Kavli Science Journalism Awards. The awards, administered by ... for distinguished reporting for a general audience. The Kavli Foundation ...
Cached Biology News:Exploring the last white spot on Earth 2Exploring the last white spot on Earth 3Scripps Health/the Medicines Company announce late breaking BRIDGE trial results presented at TCT 2Winners named for the 2011 AAAS Kavli Science Journalism Awards 2Winners named for the 2011 AAAS Kavli Science Journalism Awards 3Winners named for the 2011 AAAS Kavli Science Journalism Awards 4Winners named for the 2011 AAAS Kavli Science Journalism Awards 5Winners named for the 2011 AAAS Kavli Science Journalism Awards 6Winners named for the 2011 AAAS Kavli Science Journalism Awards 7Winners named for the 2011 AAAS Kavli Science Journalism Awards 8Winners named for the 2011 AAAS Kavli Science Journalism Awards 9
... Mediated Purification with an Affinity Chitin-binding Tag) ... protein splicing elements (termed inteins) to purify ... (1-4) (Figures 1 and 2). This system ... by its ability to separate a recombinant ...
... Kit provides the reagents to efficiently ... skeletal myotubes. By efficiently promoting myogenic ... tool in studies examining myogenesis, transcription ... for muscle cell replacement therapy. By ...
The Saturn 2200 answers your GC/MS questions with the CP-3800 GC and the 2000 Series Ion Trap MS! These components create a platform for the worlds most versatile GC and flexible MS. Both deliver une...
... of E-PAGE Gels easier and more efficient ... and several types of pre-cut pre-assembled membrane/filter ... x 13.5 cm E-PAGE Gels*. The available ... for western transfer of proteins (Figure 1 ...
Biology Products: